The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Cancer risks in BRCA2 families: estimates for sites other than breast and ovary
Open accessAbstract
Background: In BRCA2 mutation carriers, increased risks have been reported for several cancer sites besides breast and ovary. As most of the families included in earlier reports were selected on the basis of multiple breast/ovarian cancer cases, it is possible that risk estimates may differ in mutation carriers with a less striking family history. Methods: In the Netherlands, 139 BRCA2 families with 66 different pathogenic mutations were included in a nationwide study. To avoid testing bias, we chose not to estimate risk in typed carriers, but rather in male and female family members with a 50% prior probability of being a carrier (n = 1811). The relative risk (RR) for each cancer site with the exception of breast and ovarian cancer was determined by comparing observed numbers with those expected, based on Dutch cancer incidence rates. Results: We observed an excess risk for four cancer sites: pancreas (RR 5.9; 95% confidence interval (CI) 3.2 to 10.0), prostate (2.5; 1.6 to 3.8), bone (14.4; 2.9 to 42.1) and pharynx (7.3; 2.0 to 18.6). A small increase was observed for cancer of the digestive tract (1.5; 1.1 to 1.9). Histological verification was available for 46% of the tumours. Nearly all increased risks reached statistical significance for men only. Cancer risks tended to be higher for people before the age of 65 years. Moreover, families with mutations outside the previously defined ovarian cancer cluster region tended to have a higher cancer risk. Conclusions: We found that BRCA2 carriers are at increased risk for cancers of the prostate and pancreas, and possibly bone and pharynx. Larger databases with extended follow up are needed to provide insight into mutation specific risks of selected carriers in BRCA2 families.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Incidence in Five Continents
(1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,501
Cancer Incidence in Five Continents
(1966) · doi:10.1007/978-3-642-85849-9 · Cited by 5,936
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
Self-citationThe Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,281
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Cancer Risks in BRCA2 Mutation Carriers
Breast Cancer Linkage Consortium, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,527
Cancer Incidence in BRCA1 Mutation Carriers
Thompson, D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1358 · Cited by 1,096
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Kwan, E., Jack, E., Vesprini, D. J., Kuperstein, G., Abrahamson, J. L. A., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318787 · Cited by 986
Fritz, W. (1982) · Food / Nahrung · doi:10.1002/food.19820260329 · Cited by 824
Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
Brose, M. S. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1365 · Cited by 728
Natural History of Early, Localized Prostate Cancer
Johansson, J.-E. (2004) · JAMA · doi:10.1001/jama.291.22.2713 · Cited by 703
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.
Goggins, M., Schutte, M. E. M., Lü, J., Moskaluk, C. A., Weinstein, C. L., Petersen, G. M., Yeo, C. J., Jackson, C. E., Lynch, H. T., Hruban, R. H., et al. (1996) · PubMed · Cited by 642
Variation in Cancer Risks, by Mutation Position, in BRCA2 Mutation Carriers
Thompson, D., & Easton, D. (2001) · The American Journal of Human Genetics · doi:10.1086/318181 · Cited by 489
BRCA2 germline mutations in familial pancreatic carcinoma
Hahn, S. A., Greenhalf, B., Ellis, I., Sina-Frey, M., Rieder, H., Korte, B., Gerdes, B., Kress, R., Ziegler, A., Raeburn, J. A., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.3.214 · Cited by 480
Second cancer risk following Hodgkin's disease: a 20-year follow-up study.
van Leeuwen, F. E., Klokman, W. J., Hagenbeek, A., Noyon, R., van den Belt-Dusebout, A. W., van Kerkhoff, E. H., van Heerde, P., & Somers, R. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.312 · Cited by 443
Self-citationGayther, S. A., Mangion, J., Russell, P., Seal, S., Barfoot, R., Ponder, B. A. J., Stratton, M. R., & Easton, D. (1997) · Nature Genetics · doi:10.1038/ng0197-103 · Cited by 442
Murphy, K. M., Brune, K. A., Griffin, C. A., Sollenberger, J. E., Petersen, G. M., Bansal, R. K., Hruban, R. H., & Kern, S. E. (2002) · PubMed · Cited by 435
Cancer Risks in Two Large Breast Cancer Families Linked to BRCA2 on Chromosome 13q12‐13
Easton, D. F., Steele, L., Fields, P., Ormiston, W., Averill, D., Daly, P. A., McManus, R., Neuhausen, S. L., Ford, D., Wooster, R., et al. (1997) · The American Journal of Human Genetics · doi:10.1086/513891 · Cited by 387
Two Percent of Men with Early-Onset Prostate Cancer Harbor Germline Mutations in the BRCA2 Gene
Edwards, S. M., Kote-Jarai, Z., Meitz, J., Hamoudi, R., Hope, Q., Osin, P., Jackson, R., Southgate, C., Singh, R., Falconer, A., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/345310 · Cited by 366
Population-based study of risk of breast cancer in carriers of BRCA2 mutation
Thorlacius, S., Struewing, J. P., Hartage, P., Olafsdottir, G. H., Sigvaldason, H., Tryggvadottir, L., Wacholder, S., Tulinius, H., & Eyfjörd, J. E. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03300-5 · Cited by 348
Punglia, R. S., D'Amico, A. V., Catalona, W. J., Roehl, K. A., & Kuntz, K. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021659 · Cited by 326
Lal, G., Liu, G., Schmocker, B., Kaurah, P., Özçelik, H., Narod, S. A., Redston, M. S., & Gallinger, S. (2000) · PubMed · Cited by 231
Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients
Özcelik, H., Schmocker, B., Nicola, N. D., Shi, X.-H., Langer, B., Moore, M., Taylor, B. R., Narod, S. A., Darlington, G., Andrulis, I. L., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-17 · Cited by 225
The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan, J. M., Offit, K., Foulkes, W. D., Robson, M. E., Wacholder, S., Eng, C. M., Karp, S. E., & Begg, C. B. (2001) · PubMed · Cited by 218
BRCA2 Is Inactivated Late in the Development of Pancreatic Intraepithelial Neoplasia
Goggins, M., Hruban, R. H., & Kern, S. E. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65047-x · Cited by 212
Shared Genetic Susceptibility to Breast Cancer, Brain Tumors, and Fanconi Anemia
Offit, K., Levran, O., Mullaney, B., Mah, K., Nafa, K., Batish, S. D., Diotti, R., Schneider, H., Deffenbaugh, A., Scholl, T., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg072 · Cited by 201
On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance
Begg, C. B. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1221 · Cited by 201
Schutte, M., da Costa, L. T., Hahn, S. A., Moskaluk, C., Hoque, A. T., Rozenblum, E., Weinstein, C. L., Bittner, M., Meltzer, P. S., & Trent, J. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.13.5950 · Cited by 163
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2
Neibergs, H. L. (2004) · The Women s Oncology Review · doi:10.1080/14733400410001682970 · Cited by 152
Incidence of cancer in the Netherlands.
Visser, O. J., Coebergh, J. W. W., Schouten, L. J., et al. (2001) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 138
BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.
Niell, B., Rennert, G., Bonner, J., Almog, R., Tomsho, L., & Gruber, S. (2004) · Journal of the National Cancer Institute · doi:10.1093/jnci/djh008 · Cited by 98
The effect of a single BRCA2 mutation on cancer in Iceland
Tulinius, H., Ólafsdóttir, G. H., Sigvaldason, H., Arason, A., Barkardottir, R. B., Egilsson, V., Ogmundsdottir, H. M., Tryggvadóttír, L., Gudlaugsdottir, S., & Eyfjord, J. E. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.7.457 · Cited by 89
Contribution of Germline Mutations in BRCA2 , P16 INK4A , P14 ARF and P15 to Uveal Melanoma
Hearle, N., Damato, B. E., Humphreys, J., Wixey, J., Green, H. E., Stone, J. G., Easton, D. F., & Houlston, R. S. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-0026 · Cited by 72
The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel
Vazina, A., Baniel, J., Yaacobi, Y., Shtriker, A., Engelstein, D., Leibovitz, I., Zehavi, M., Sidi, A., Ramon, Y., Tischler, T., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1249 · Cited by 61
A BRCA2 germ-line mutation in familial pancreatic carcinoma
White, K., Held, K. R., & Weber, B. H. F. (2001) · International Journal of Cancer · Cited by 18
Cited by
Syngal, S., Brand, R. E., Church, J. M., Giardiello, F. M., Hampel, H. L., & Burt, R. W. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.435 · Cited by 1,662
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V., Czito, B., Del Chiaro, M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0017 · Cited by 1,304
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Metadata
- Authors
- van Asperen, C. J., Brohet, R. M., Meijers-Heijboer, E. J., Hoogerbrugge, N., Verhoef, S., Vasen, H. F. A., Ausems, M. G. E. M., Menko, F. H., Gomez Garcia, E. B., Klijn, J. G. M., Hogervorst, F. B. L., van Houwelingen, J. C., van’t Veer, L. J., Rookus, M. A., & van Leeuwen, F. E.
- Venue
- Journal of Medical Genetics
- Publisher
- BMJ
- Published
- 2005-09
- Volume
- 42
- Issue
- 9
- Pages
- 711-719
- ISSN
- 0022-2593 (ISSN-L)
- 1468-6244
- OpenAlex
- W2130414070
- Cited by
- 420
- References
- 37
- FWCI
- 8.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.